CO6241152A2 - 3-(imidazolil)-pirazolo[3, 4-b] piridinas - Google Patents

3-(imidazolil)-pirazolo[3, 4-b] piridinas

Info

Publication number
CO6241152A2
CO6241152A2 CO09132269A CO09132269A CO6241152A2 CO 6241152 A2 CO6241152 A2 CO 6241152A2 CO 09132269 A CO09132269 A CO 09132269A CO 09132269 A CO09132269 A CO 09132269A CO 6241152 A2 CO6241152 A2 CO 6241152A2
Authority
CO
Colombia
Prior art keywords
compound
pharmaceutically acceptable
glyoxal
imidazole
formula
Prior art date
Application number
CO09132269A
Other languages
English (en)
Spanish (es)
Inventor
Lianfa Li
Andrew M K Pennell
Penglie Zhang
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of CO6241152A2 publication Critical patent/CO6241152A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CO09132269A 2007-05-22 2009-11-20 3-(imidazolil)-pirazolo[3, 4-b] piridinas CO6241152A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93294807P 2007-05-22 2007-05-22

Publications (1)

Publication Number Publication Date
CO6241152A2 true CO6241152A2 (es) 2011-01-20

Family

ID=40075474

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09132269A CO6241152A2 (es) 2007-05-22 2009-11-20 3-(imidazolil)-pirazolo[3, 4-b] piridinas

Country Status (26)

Country Link
US (4) US7629344B2 (enExample)
EP (1) EP2155712B1 (enExample)
JP (1) JP5457338B2 (enExample)
KR (1) KR101534661B1 (enExample)
CN (1) CN101743238B (enExample)
AR (2) AR066701A1 (enExample)
AU (1) AU2008256862B2 (enExample)
BR (1) BRPI0811849A8 (enExample)
CA (1) CA2687625C (enExample)
CL (1) CL2008001493A1 (enExample)
CO (1) CO6241152A2 (enExample)
DK (1) DK2155712T3 (enExample)
EA (1) EA015529B1 (enExample)
ES (1) ES2600477T3 (enExample)
HU (1) HUE032273T2 (enExample)
IL (1) IL202248A (enExample)
JO (1) JO3319B1 (enExample)
MA (1) MA31442B1 (enExample)
MX (1) MX2009012567A (enExample)
NZ (1) NZ581405A (enExample)
PE (1) PE20090293A1 (enExample)
PL (1) PL2155712T3 (enExample)
PT (1) PT2155712T (enExample)
TW (1) TWI418353B (enExample)
UA (1) UA99619C2 (enExample)
WO (1) WO2008147815A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7777035B2 (en) * 2005-06-22 2010-08-17 Chemocentryx, Inc. Azaindazole compounds and methods of use
PT2081921E (pt) 2006-07-10 2010-12-10 Paion Uk Ltd Sais de benzodiazepina de acção curta e suas formas polimórficas
NZ581405A (en) * 2007-05-22 2011-06-30 Chemocentryx Inc 3-(Imidazolyl)-pyrazolo[3,4-b]pyridines and their use in treating CCR1-mediated disorders
BRPI0918517B8 (pt) 2008-09-11 2021-05-25 Chemocentryx Inc composto, composição farmacêutica, e, uso de um composto
EP2305647A1 (en) 2009-09-18 2011-04-06 PAION UK Limited Process for preparing 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4 H-imidazo[1,2-a][1,4]benzodiazepine-4-yl] propionic acid methyl ester or the benzene sulfonate salt thereof, and compounds useful in that process
EP2450039A1 (en) 2010-11-08 2012-05-09 PAION UK Ltd. Dosing regimen for sedation with CNS 7056 (Remimazolam)
SG11201501479QA (en) * 2012-08-27 2015-04-29 Chemocentryx Inc Antagonists of chemokine receptors
SG11201504410PA (en) * 2012-12-07 2015-07-30 Chemocentryx Inc Diazole lactams
AR094963A1 (es) 2013-03-04 2015-09-09 Ono Pharmaceutical Co Reacción de oxidación excelente en el índice de conversión
US20170195506A1 (en) * 2015-12-30 2017-07-06 Kabushiki Kaisha Toshiba Image forming apparatus forming location free print system and print job retrieval method by the same
AU2017246460B2 (en) 2016-04-07 2021-04-22 Chemocentryx, Inc. Reducing tumor burden by administering CCR1 antagonists in combination with PD-1 inhibitors or PD-L1 inhibitors
KR102890201B1 (ko) 2019-07-10 2025-11-24 케모센트릭스, 인크. Pd-l1 억제제로서의 인단
PH12022550877A1 (en) 2019-10-16 2023-03-27 Chemocentryx Inc Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases
JP7736678B2 (ja) 2019-10-16 2025-09-09 ケモセントリックス，インコーポレイティド Ｐｄ－ｌ１疾患の処置のためのヘテロアリール－ビフェニルアミド

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US715746A (en) * 1902-02-25 1902-12-16 Nat Tube Co Apparatus for handling tube-plates.
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
IE47467B1 (en) * 1977-10-26 1984-03-21 Wellcome Found Imidazoline derivatives and their salts
AU518569B2 (en) * 1979-08-07 1981-10-08 Farmos-Yhtyma Oy 4-benzyl- and 4-benzoyl imidazole derivatives
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
LU86084A1 (fr) 1985-09-20 1987-04-02 Faco Sa Apparei de massage electrique
US5102417A (en) 1985-11-07 1992-04-07 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4800882A (en) 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US4886062A (en) 1987-10-19 1989-12-12 Medtronic, Inc. Intravascular radially expandable stent and method of implant
US4927942A (en) * 1988-12-15 1990-05-22 Texaco Chemical Co. Method for the preparation of imidazoles
WO1990013332A1 (en) 1989-05-11 1990-11-15 Cedars-Sinai Medical Center Stent with sustained drug delivery
DE69110787T2 (de) 1990-02-28 1996-04-04 Medtronic, Inc., Minneapolis, Minn. Intraluminale prothese mit wirkstoffeluierung.
US5419760A (en) 1993-01-08 1995-05-30 Pdt Systems, Inc. Medicament dispensing stent for prevention of restenosis of a blood vessel
US5429634A (en) 1993-09-09 1995-07-04 Pdt Systems Biogenic implant for drug delivery and method
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
US5833651A (en) 1996-11-08 1998-11-10 Medtronic, Inc. Therapeutic intraluminal stents
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US20050256130A1 (en) * 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
US7842693B2 (en) * 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
US7589199B2 (en) * 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
KR101255356B1 (ko) * 2002-06-12 2013-04-17 케모센트릭스, 인크. 염증 및 면역 질병의 치료를 위한 ｃｃｒ１ 길항물질로서사용하기 위한 1-아릴-4-치환된 피페라진 유도체
US6770729B2 (en) 2002-09-30 2004-08-03 Medtronic Minimed, Inc. Polymer compositions containing bioactive agents and methods for their use
US7435831B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US7435830B2 (en) * 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US7777035B2 (en) * 2005-06-22 2010-08-17 Chemocentryx, Inc. Azaindazole compounds and methods of use
EA017278B9 (ru) * 2005-06-22 2013-01-30 Кемосентрикс, Инк. Соединения азаиндазола и способы применения
KR200434921Y1 (ko) * 2006-07-10 2007-01-02 서용석 야외용 간이 화장실
NZ581405A (en) * 2007-05-22 2011-06-30 Chemocentryx Inc 3-(Imidazolyl)-pyrazolo[3,4-b]pyridines and their use in treating CCR1-mediated disorders

Also Published As

Publication number Publication date
US20120010214A1 (en) 2012-01-12
KR20100022998A (ko) 2010-03-03
CA2687625A1 (en) 2008-12-04
EA200901572A1 (ru) 2010-04-30
CL2008001493A1 (es) 2008-08-29
PL2155712T3 (pl) 2017-02-28
EP2155712A1 (en) 2010-02-24
BRPI0811849A8 (pt) 2019-01-15
KR101534661B1 (ko) 2015-07-09
US7960388B2 (en) 2011-06-14
EP2155712B1 (en) 2016-09-07
CN101743238A (zh) 2010-06-16
CN101743238B (zh) 2014-04-30
EA015529B1 (ru) 2011-08-30
US20100173911A1 (en) 2010-07-08
WO2008147815A1 (en) 2008-12-04
US8481545B2 (en) 2013-07-09
UA99619C2 (en) 2012-09-10
IL202248A (en) 2015-04-30
PT2155712T (pt) 2016-12-13
PE20090293A1 (es) 2009-04-04
AU2008256862B2 (en) 2013-01-31
BRPI0811849A2 (pt) 2014-11-18
JO3319B1 (ar) 2019-03-13
IL202248A0 (en) 2010-06-16
DK2155712T3 (en) 2016-12-19
JP5457338B2 (ja) 2014-04-02
EP2155712A4 (en) 2011-05-11
ES2600477T3 (es) 2017-02-09
CA2687625C (en) 2015-12-22
US7629344B2 (en) 2009-12-08
JP2010528038A (ja) 2010-08-19
AR066701A1 (es) 2009-09-09
TWI418353B (zh) 2013-12-11
AR110128A2 (es) 2019-02-27
NZ581405A (en) 2011-06-30
AU2008256862A8 (en) 2009-12-24
MX2009012567A (es) 2010-02-17
HUE032273T2 (en) 2017-09-28
AU2008256862A1 (en) 2008-12-04
TW200906402A (en) 2009-02-16
US20130184289A1 (en) 2013-07-18
HK1141524A1 (zh) 2010-11-12
MA31442B1 (fr) 2010-06-01
US20080300257A1 (en) 2008-12-04

Similar Documents

Publication Publication Date Title
CO6241152A2 (es) 3-(imidazolil)-pirazolo[3, 4-b] piridinas
AR085155A1 (es) Procesos para preparar compuestos de quinolina y composiciones farmaceuticas que contienen dichos compuestos
AR072199A1 (es) Derivados de fenilimidazol como inhibidores de la enzima pde10a
JO3073B1 (ar) مثبطات ثنائية ملتحمة ثلاثية الحلقة ل cdk 4/6 و flt3
CO6390081A2 (es) Compuestos organicos
MD20140084A2 (en) New indolizine derivatives, method for preparing same and pharmaceutical compositions containing same
NZ606001A (en) Derivatives of 1-amino-2-cyclobutylethylboronic acid
WO2009146034A3 (en) Mapk/erk kinase inhibitors and methods of use thereof
CO6260141A2 (es) Inhibidores del co-transportador 2 sodio glucosa y metodos para la preparacion de los mismos y sus intermediarios
MY150542A (en) Cmet inhibitors
NZ598972A (en) Spiro-indoline-piperidine derivatives as selective GPR-40 activators for treating diabetes
AU2015221439B2 (en) Crystalline 6,7-unsaturated-7-carbamoyl morphinane derivative, and method for producing same
AR087863A1 (es) Procedimientos para la formacion de complejos de ciclodextrina para formular inhibidores del proteasoma peptidico
BR112012006639A2 (pt) métodos para preparar derivados de pirimidina úteis como inibidores de protéina quinase
MY150778A (en) Fused heterocyclic compound
AR084757A1 (es) Procedimiento de inmovilizacion de ligandos nucleicos
MX2009003257A (es) Procedimiento para la sintesis de derivados de fenoxi diaminopirimidina.
UA107779C2 (en) Method of synthetic 7,8-dimethoxy-1,3-dihydro-2h-3-benzazepin-2-one and use in the synthesis ivabradynu and its addition salts with pharmaceutically acceptable acid
HRP20140837T1 (hr) Organske aminske soli 6-fluoro-3-hidroksi-2-pirazinkarbonitrila i postupak za proizvodnju istih
UY31460A1 (es) Procedimiento de preparacion de compuestos morfinicos
AR085349A1 (es) Metodo para preparar un precursor de catalizador y proceso de sintesis de hidrocarburos
AR084864A1 (es) Proceso de preparacion de girasa e inhibidores de topoisomerasa iv y compuestos intermediarios de dicho proceso
CL2010001441A1 (es) Proceso para la preparacion de derivados de 2-amino tiazolonas sustituidas utilizando derivados de efedrina como base quiral.
AR080025A1 (es) Derivados de 8-aza-biciclo[3,2,1] oct-3-iloxi)-cromen-2-ona, utiles como inhibidores de la recaptacion del neurotransmisor monoamina
UA118008C2 (uk) Спосіб синтезу (2е)-3-(3,4-диметоксифеніл)проп-2-еннітрилу та застосування в синтезі івабрадину та його адитивних солей з фармацевтично прийнятною кислотою

Legal Events

Date Code Title Description
FC Application refused
FG Application granted